CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Access to Modern Radiotherapy Technology in Low- and Middle-Income Countries: Obstacles and Opportunities

Access to Modern Radiotherapy...

How Is Radiation Therapy Benefiting Healthcare Sector

How Is Radiation Therapy Benefiting...

Multiomic Preclinical Models to Define the Mechanism of Action

Multiomic Preclinical Models to...

Developing Patient-Centric Precision Oncology Therapies: Begin With The End In Mind

Developing Patient-Centric Precision...

What the New EMA Draft

What the New EMA Draft "Guideline on...

Pharmaceutical Tablet Coating - Past, Present and Future

Pharmaceutical Tablet Coating - Past,...

Dynamic Commercial Aspects  of Life Sciences

Dynamic Commercial Aspects of Life...

Achieving trial master file quality, timeliness and completeness

Achieving trial master file quality,...

Access to Modern Radiotherapy Technology in Low- and Middle-Income Countries: Obstacles and Opportunities

Access to Modern Radiotherapy...

How Is Radiation Therapy Benefiting Healthcare Sector

How Is Radiation Therapy Benefiting...

Multiomic Preclinical Models to Define the Mechanism of Action

Multiomic Preclinical Models to...

Developing Patient-Centric Precision Oncology Therapies: Begin With The End In Mind

Developing Patient-Centric Precision...

What the New EMA Draft

What the New EMA Draft "Guideline on...

Pharmaceutical Tablet Coating - Past, Present and Future

Pharmaceutical Tablet Coating - Past,...

Dynamic Commercial Aspects  of Life Sciences

Dynamic Commercial Aspects of Life...

Achieving trial master file quality, timeliness and completeness

Achieving trial master file quality,...

Reasons why Modern Radiotherapy Technology Access is Limited in Low- and Middle-Income Countries

Life Sciences Review | Thursday, October 20, 2022
Tweet

Radiotherapy technology is an essential component of the cancer care provided by LMICs. Implementing it in these countries poses unique challenges and provides novel opportunities for improving access to cancer care since it can effectively bridge geographical barriers.


FREMONT, CA: Radiation therapy is an important cancer treatment strategy. Nearly half of all cancer patients need radiotherapy as part of their treatment plan. This is the mainstay of definitive treatment for advanced cancer sites such as the head/neck, cervix, and prostate. Low- and middle-income countries (LMICs) have disproportionately higher rates of these cancers, which tend to be detected earlier when they are inoperable.


Consequently, the demand for radiotherapy in LMICs is even higher, both for definitive and palliative therapy. This is because the localized requirement for radiotherapy is even higher. Accordingly, radiotherapy plays a major role in cancer care planning in LMICs. It must be readily available in both quantity and quality. The rapid evolution of radiotherapy technology has influenced therapeutic management across various cancer sites. Still, many barriers prevent the benefits of these advancements from reaching patients with cancer living in the least developed countries.


Clinical outcomes of radiotherapy across cancer sites are affected by the technological status of radiotherapy resources. A growing number of LMICs will see a 70 percent-100 percent increase in locally advanced cancers in the breast, lungs, and head and neck regions as a result of radiotherapy.


With the advent of modern radiotherapy equipment, 


technological advancements have radically transformed the delivery of radiation for these cancers over conventional radiotherapy based on telecobalt. Technology has significantly contributed to reducing treatment-related toxicity and improving treatment tolerance. Intensity-modulated radiation treatment (IMRT) in treating head/neck cancer reduces the incidence and severity of late treatment-related morbidities, including dysphagia, xerostomia, weight loss, trismus, fibrosis, and hearing impairments.


In high-income and low-income countries, many barriers to accessing high-quality radiotherapy technologies have been identified. Several patient and physician factors, such as age, comorbid conditions, and lower awareness, were identified as significant factors affecting the lower utilization of IMRT/image-guided radiotherapy in European nations, including physician referral bias, physician preferences, and geographical factors (distance from residence, imbalanced distribution of treatment centers).


It is essential to be aware of barriers to technological access, both at the policy and decision-making levels, as well as to understand the value of high-quality radiotherapy at all policy- and decision-making levels. There is a strong need to involve clinical experts in the policy definition process, as well as a ground-level estimation of future technological needs at present and in the future, to achieve the desired access to quality radiotherapy.


With modern techniques such as intensity modulation, image guidance, stereotactic ablation, and integration of radiological and functional imaging into radiotherapy planning, radiation oncology has changed its face as an integral component of cancer treatment.


Weekly Brief

loading
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue

Read Also

Hepion Pharmaceuticals to Get a Total of $ 3.2 Million in Non-Dilutive Financing

Benefits that Medical Writing Offers

Antibodies: Immunoglobulin Isotypes

Life Science Consulting Services Trends

Rani Therapeutics and Celltrion Partner to Develop Oral Monoclonal Antibodies

ProPhase Labs Acquires BE-Smart Esophageal Pre-Cancer Screening Test

The Influence of Pharmaceutical Distributors on U.S. Drug Expenditures

Tips to Improve Medical Writing

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/reasons-why-modern-radiotherapy-technology-access-is-limited-in-low-and-middleincome-countries-nwid-1013.html